Article ; Online: Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting.
Journal of hematology & oncology
2024 Volume 17, Issue 1, Page(s) 18
Abstract: The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; ... ...
Abstract | The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; several prospective studies involving these drugs have demonstrated high remission rates and promising, albeit short, survival outcomes. This review summarizes the latest updates on chemo-free regimens in the treatment of adult patients with Ph + ALL, presented at the 2023 ASH annual meeting. |
---|---|
MeSH term(s) | Adult ; Humans ; Prospective Studies ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Philadelphia Chromosome |
Chemical Substances | Protein Kinase Inhibitors |
Language | English |
Publishing date | 2024-04-16 |
Publishing country | England |
Document type | Review ; Letter ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2429631-4 |
ISSN | 1756-8722 ; 1756-8722 |
ISSN (online) | 1756-8722 |
ISSN | 1756-8722 |
DOI | 10.1186/s13045-024-01539-4 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.